Ionis Pharmaceuticals Inc (IONS) shareholders
Close on Nov 17, 2026Market cap $4.48BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (15.00%) | 21,520,872 | 15.00% | 13G (passive) amendment | Feb 9, 2024 |
| Capital World Investors | 21,186,369 | 12.80% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 9,066,517 | 5.70% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 8,344,732 | 5.05% | 13G (passive) | Mar 31, 2026 |
| Biotech Invest N.V. Joint filing with BB Biotech AG (5.00%) | 7 | 5.00% | 13G (passive) amendment | Nov 14, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IONS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 24,631,956 | 14.82% | $1.95B | +75,319 | 0.08% |
| Capital World Investors | 21,669,226 | 13.04% | $1.72B | +482,857 | 0.20% |
| BlackRock, Inc. | 10,704,660 | 6.44% | $848.77M | +262,184 | 0.01% |
| Vanguard Portfolio Management LLC | 7,859,529 | 4.73% | $623.18M | +50,627 | 0.03% |
| Wellington Management Group Llp | 7,651,415 | 4.60% | $606.68M | +1,259,599 | 0.10% |
| Vanguard Capital Management LLC | 7,211,497 | 4.34% | $571.80M | +93,167 | 0.01% |
| Two Sigma Investments, LP | 6,252,342 | 3.76% | $495.75M | +394,713 | 0.36% |
| Royal Bank of Canada | 6,182,479 | 3.72% | $490.21M | +2,380,664 | 0.07% |
| State Street Corp | 4,334,848 | 2.61% | $343.71M | +339,284 | 0.01% |
| T. Rowe Price Investment Management, Inc. | 3,959,372 | 2.38% | $313.94M | −2,199,655 | 0.21% |
| Geode Capital Management, LLC | 3,584,024 | 2.16% | $294.75M | −400,308 | 0.02% |
| Price T Rowe Associates Inc /Md/ | 3,184,500 | 1.92% | $252.50M | +159,249 | 0.03% |
| JPMorgan Chase & Co | 2,671,717 | 1.61% | $216.20M | +308,150 | 0.01% |
| Artisan Partners Limited Partnership | 2,640,024 | 1.59% | $209.33M | +581,716 | 0.33% |
| Tweedy, Browne Co LLC | 2,280,311 | 1.37% | $180.81M | +4,686 | 13.70% |
| Deep Track Capital, LP | 2,200,000 | 1.32% | $174.44M | +250,000 | 2.54% |
| Goldman Sachs Group Inc | 2,109,945 | 1.27% | $167.30M | +410,098 | 0.01% |
| Baker Bros. Advisors LP | 2,047,727 | 1.23% | $162.36M | – | 0.81% |
| Deerfield Management Company, L.P. (Series C) | 1,979,669 | 1.19% | $156.97M | – | 1.64% |
| American Century Companies Inc | 1,947,076 | 1.17% | $154.38M | +283,273 | 0.07% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 513 | 180M | 100.0% | 67 / 201 | 160 / 46 | 19M | 12M |
| Q1 2026 | 496 | 173M | 100.0% | 73 / 178 | 158 / 66 | 38M | 25M |
| Q4 2025 | 493 | 176M | 100.0% | 111 / 168 | 141 / 43 | 26M | 18M |
| Q3 2025 | 436 | 169M | 100.0% | 114 / 135 | 117 / 38 | 21M | 22M |
| Q2 2025 | 363 | 170M | 100.0% | 80 / 120 | 110 / 59 | 17M | 14M |
| Q1 2025 | 344 | 167M | 100.0% | 54 / 102 | 123 / 59 | 18M | 12M |
| Q4 2024 | 355 | 160M | 96.6% | 58 / 119 | 120 / 50 | 17M | 15M |
| Q3 2024 | 354 | 158M | 95.1% | 53 / 130 | 108 / 52 | 34M | 10M |
| Q2 2024 | 357 | 145M | 87.0% | 52 / 120 | 132 / 53 | 15M | 15M |
| Q1 2024 | 361 | 145M | 87.5% | 49 / 123 | 128 / 50 | 11M | 11M |
| Q4 2023 | 364 | 145M | 87.3% | 85 / 109 | 115 / 28 | 15M | 10M |
| Q3 2023 | 311 | 140M | 84.2% | 38 / 103 | 102 / 27 | 13M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
451 funds held IONS in Q2 2026, 28% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IONS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 8,471,732 | 5.10% | $648.09M | 0.66% | May 31, 2026 |
| Growth Fund of America | 7,668,655 | 4.61% | $586.65M | 0.16% | May 31, 2026 |
| Vanguard Health Care Fund | 6,212,640 | 3.74% | $321.63M | 0.84% | Jul 31, 2026 |
| SMALLCAP World Fund Inc | 5,259,919 | 3.17% | $417.06M | 0.44% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,989,044 | 3.00% | $395.58M | 0.02% | Jun 30, 2026 |
| New Economy Fund | 4,868,802 | 2.93% | $372.46M | 0.72% | May 31, 2026 |
| Vanguard Small-Cap Index Fund | 3,597,995 | 2.17% | $285.29M | 0.15% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 2,348,458 | 1.41% | $179.66M | 0.65% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 2,090,022 | 1.26% | $159.89M | 0.65% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 2,075,497 | 1.25% | $164.57M | 0.35% | Jun 30, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1,998,674 | 1.20% | $158.47M | 0.69% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,894,588 | 1.14% | $150.22M | 0.15% | Jun 30, 2026 |
| Tweedy, Browne International Value Fund | 1,743,125 | 1.05% | $138.21M | 3.25% | Jun 30, 2026 |
| Growth Fund | 1,674,900 | 1.01% | $132.80M | 0.23% | Jun 30, 2026 |
| Vanguard Explorer Fund | 1,465,677 | 0.88% | $75.88M | 0.34% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Brett P. Monia | Chief Executive Officer, Director | 242,760 | 0.15% | Sep 2, 2026 |
| Eric Swayze | EVP Research | 22,149 | 0.01% | Oct 19, 2026 |
| Shannon L. Devers | EVP, Chief Human Resources Ofc | 17,811 | 0.01% | Oct 19, 2026 |
| Brian Birchler | EVP, Corp and Development Ops | 102,883 | 0.06% | Sep 2, 2026 |
| C. Frank Bennett | EVP, Chief Scientific Officer | 75,128 | 0.05% | Sep 2, 2026 |
| Patrick R. O'Neil | EVP CLO & General Counsel | 59,205 | 0.04% | Sep 2, 2026 |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | 22,096 | 0.01% | Jul 9, 2026 |
| Joseph Baroldi | EVP, Chief Business Officer | 53,191 | 0.03% | Jun 30, 2026 |
| Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 77,114 | 0.05% | Jun 30, 2026 |
| Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | 23,713 | 0.01% | Apr 17, 2026 |
| Elizabeth L. Hougen | EVP, Finance & CFO | 82,660 | 0.05% | Mar 18, 2026 |
| Richard S. Geary | EVP, Chief Development Officer | 59,657 | 0.04% | Nov 7, 2025 |
| Michael R. Hayden | Director | 81,298 | 0.05% | Nov 13, 2026 |
| Joan E. Herman | Director | 51,306 | 0.03% | Jul 17, 2026 |
| Spencer R. Berthelsen | Director | 161,303 | 0.10% | Jul 17, 2026 |
| Ludwig Hantson | Director | – | – | Jul 17, 2026 |
| Peter N. Reikes | Director | 14,222 | 0.01% | Jul 17, 2026 |
| Allene M. Diaz | Director | 13,922 | 0.01% | Jul 9, 2026 |
| Joseph Klein Iii | Director | 11,214 | 0.01% | Jul 6, 2026 |
| Michael J. Yang | Director | 7,940 | 0.00% | Jul 6, 2026 |
| Joseph Loscalzo | Director | 54,111 | 0.03% | Jul 6, 2026 |
| B. Lynne Parshall | Director | 52,878 | 0.03% | Apr 17, 2026 |
| Joseph H. Wender | Director | 52,035 | 0.03% | Dec 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael R. Hayden Director | Nov 10, 2026 | Buy | +5,000 | $29.64 | $148.20K | 27,000 |
| Shannon L. Devers EVP, Chief Human Resources Ofc | Oct 16, 2026 | Sale | −1,357 | $43.54 | $59.08K | 17,811 |
| Eric Swayze EVP Research | Oct 16, 2026 | Sale | −53 | $43.54 | $2.31K | 390 |
| Shannon L. Devers EVP, Chief Human Resources Ofc | Oct 15, 2026 | Option exercise | +2,820 | – | – | 19,168 |
| Eric Swayze EVP Research | Oct 15, 2026 | Option exercise | +125 | – | – | 443 |
| Patrick R. O'Neil EVP CLO & General Counsel | Aug 31, 2026 | Other | +63 | $51.31 | $3.23K | 59,205 |
| Brett P. Monia Chief Executive Officer, Director | Aug 31, 2026 | Other | +98 | $51.31 | $5.03K | 242,760 |
| C. Frank Bennett EVP, Chief Scientific Officer | Aug 31, 2026 | Other | +110 | $51.31 | $5.64K | 60,128 |
| Brian Birchler EVP, Corp and Development Ops | Aug 31, 2026 | Other | +58 | $51.31 | $2.98K | 102,883 |
| Michael R. Hayden Director | Jul 31, 2026 | Buy | +5,000 | $51.60 | $258.00K | 24,000 |
| Michael R. Hayden Director | Jul 30, 2026 | Buy | +15,000 | $53.38 | $800.70K | 19,000 |
| Joan E. Herman Director | Jul 15, 2026 | Option exercise | +5,220 | – | – | 51,306 |
| Spencer R. Berthelsen Director | Jul 15, 2026 | Option exercise | +5,220 | – | – | 161,233 |
| Allene M. Diaz Director | Jul 7, 2026 | Option exercise | +10,111 | $47.11 | $476.33K | 13,922 |
| Allene M. Diaz Director | Jul 7, 2026 | Sale(10b5-1 plan) | −10,111 | $85.42 | $863.68K | 3,811 |
| C. Frank Bennett EVP, Chief Scientific Officer | Jul 7, 2026 | Other | +15,000 | – | – | 15,000 |
| C. Frank Bennett EVP, Chief Scientific Officer | Jul 7, 2026 | Sale(10b5-1 plan) | −5,536 | $83.58 | $462.70K | 75,018 |
| C. Frank Bennett EVP, Chief Scientific Officer | Jul 7, 2026 | Sale(10b5-1 plan) | −15,000 | $85.46 | $1.28M | 0 |
| Holly B. Kordasiewicz EVP, Chief Development Officer | Jul 7, 2026 | Sale(10b5-1 plan) | −362 | $84.30 | $30.52K | 22,096 |
| Joseph Klein Iii Director | Jul 1, 2026 | Sale(10b5-1 plan) | −11,419 | $79.04 | $902.56K | 11,014 |
| Joseph Klein Iii Director | Jul 1, 2026 | Sale(10b5-1 plan) | −99 | $79.45 | $7.87K | 22,433 |
| Joseph Klein Iii Director | Jul 1, 2026 | Option exercise | +11,518 | $39.94 | $460.03K | 22,532 |
| Patrick R. O'Neil EVP CLO & General Counsel | Jun 26, 2026 | Sale(10b5-1 plan) | −3,069 | $80.00 | $245.52K | 61,470 |
| Eugene Schneider EVP, Chf Clinical Develop Ofcr | Jun 26, 2026 | Sale(10b5-1 plan) | −26,000 | $81.05 | $2.11M | 77,114 |
| Eugene Schneider EVP, Chf Clinical Develop Ofcr | Jun 26, 2026 | Option exercise | +26,000 | $60.89 | $1.58M | 103,114 |
| Joseph Baroldi EVP, Chief Business Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −5,635 | $80.16 | $451.70K | 4,669 |
| Joseph Baroldi EVP, Chief Business Officer | Jun 26, 2026 | Option exercise | +1,769 | $32.60 | $57.67K | 10,304 |
| Joseph Baroldi EVP, Chief Business Officer | Jun 26, 2026 | Option exercise | +3,866 | $56.78 | $219.51K | 8,535 |
| Brett P. Monia Chief Executive Officer, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −50,000 | $80.59 | $4.03M | 245,571 |
| Brett P. Monia Chief Executive Officer, Director | Jun 26, 2026 | Option exercise | +50,000 | $56.78 | $2.84M | 295,571 |
| Brett P. Monia Chief Executive Officer, Director | Jun 25, 2026 | Sale(10b5-1 plan) | −21,072 | $78.49 | $1.65M | 245,571 |
| Brett P. Monia Chief Executive Officer, Director | Jun 25, 2026 | Option exercise | +21,072 | $32.60 | $686.95K | 266,643 |
| Eric Swayze EVP Research | Jun 25, 2026 | Sale(10b5-1 plan) | −10,602 | $79.18 | $839.47K | 21,759 |
| Brett P. Monia Chief Executive Officer, Director | Jun 24, 2026 | Option exercise | +14,565 | $32.60 | $474.82K | 260,136 |
| Brett P. Monia Chief Executive Officer, Director | Jun 24, 2026 | Sale(10b5-1 plan) | −14,565 | $78.41 | $1.14M | 245,571 |
| Spencer R. Berthelsen Director | Jun 15, 2026 | Sale(10b5-1 plan) | −8,000 | $73.49 | $587.92K | 156,013 |
| Spencer R. Berthelsen Director | Jun 15, 2026 | Option exercise | +8,000 | $24.42 | $195.36K | 164,013 |
| Holly B. Kordasiewicz EVP, Chief Development Officer | Jun 12, 2026 | Option exercise | +12,000 | $32.60 | $391.20K | 63,409 |
| Holly B. Kordasiewicz EVP, Chief Development Officer | Jun 12, 2026 | Option exercise | +21,000 | $60.89 | $1.28M | 51,409 |
| Holly B. Kordasiewicz EVP, Chief Development Officer | Jun 12, 2026 | Option exercise | +7,951 | $60.89 | $484.14K | 30,409 |
| Holly B. Kordasiewicz EVP, Chief Development Officer | Jun 12, 2026 | Sale(10b5-1 plan) | −41,004 | $73.09 | $3.00M | 42,300 |
| Holly B. Kordasiewicz EVP, Chief Development Officer | Jun 12, 2026 | Sale(10b5-1 plan) | −19,842 | $74.05 | $1.47M | 22,458 |
| Holly B. Kordasiewicz EVP, Chief Development Officer | Jun 12, 2026 | Option exercise | +19,895 | $56.78 | $1.13M | 83,304 |
| Spencer R. Berthelsen Director | Jun 1, 2026 | Sale(10b5-1 plan) | −8,000 | $75.67 | $605.36K | 156,013 |
| Spencer R. Berthelsen Director | Jun 1, 2026 | Option exercise | +8,000 | $24.42 | $195.36K | 164,013 |
| Brett P. Monia Chief Executive Officer, Director | May 14, 2026 | Option exercise | +3,220 | $32.60 | $104.97K | 245,882 |
| Brett P. Monia Chief Executive Officer, Director | May 14, 2026 | Sale(10b5-1 plan) | −3,220 | $78.68 | $253.35K | 242,662 |
| Brett P. Monia Chief Executive Officer, Director | May 13, 2026 | Sale(10b5-1 plan) | −1,316 | $78.01 | $102.66K | 242,662 |
| Brett P. Monia Chief Executive Officer, Director | May 13, 2026 | Option exercise | +1,316 | $32.60 | $42.90K | 243,978 |
| Joseph Loscalzo Director | May 4, 2026 | Sale(10b5-1 plan) | −59,508 | $74.90 | $4.46M | 54,111 |
| Joseph Loscalzo Director | May 4, 2026 | Option exercise | +16,000 | $64.80 | $1.04M | 113,619 |
| Joseph Loscalzo Director | May 4, 2026 | Sale(10b5-1 plan) | −17,781 | $75.58 | $1.34M | 36,330 |
| Joseph Loscalzo Director | May 4, 2026 | Option exercise | +12,000 | $60.20 | $722.40K | 97,619 |
| Joseph Loscalzo Director | May 4, 2026 | Option exercise | +16,000 | $42.88 | $686.08K | 85,619 |
| Joseph Loscalzo Director | May 4, 2026 | Option exercise | +10,321 | $41.08 | $423.99K | 69,619 |
| Joseph Loscalzo Director | May 4, 2026 | Option exercise | +12,000 | $40.05 | $480.60K | 59,298 |
| Joseph Loscalzo Director | May 4, 2026 | Option exercise | +10,968 | $38.06 | $417.44K | 47,298 |
| Joseph Klein Iii Director | May 1, 2026 | Sale(10b5-1 plan) | −1,431 | $74.45 | $106.54K | 11,014 |
| Joseph Klein Iii Director | May 1, 2026 | Option exercise | +10,111 | $47.11 | $476.33K | 21,125 |
| Joseph Klein Iii Director | May 1, 2026 | Sale(10b5-1 plan) | −8,680 | $73.35 | $636.68K | 12,445 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ionis Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 14,082 shares on Oct 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Shannon L. Devers Officer | Oct 16, 2026 | 1,357 | $59.71K | Oct 16, 2026 | RSUs granted under 2011 Equity Incentive Plan |
| C. Frank Bennett Officer | Jul 7, 2026 | 67,386 | $5.72M | Jul 7, 2026 | Owned Shares |
| Holly B. Kordasiewicz Officer | Jul 7, 2026 | 1,287 | $108.49K | Jul 7, 2026 | Restricted Stock |
| Allene M. Diaz Director | Jul 7, 2026 | 10,111 | $863.64K | Jul 7, 2026 | Stock Option Exercise |
| Joseph Klein Iii Director | Jul 1, 2026 | 11,518 | $910.42K | Jul 1, 2026 | Stock Option Exercise |
| Baroldi Mariana Member of immediate family of any of the foregoing | Jun 26, 2026 | 5,635 | $451.70K | Jun 26, 2026 | Stock Option Exercise |
| Patrick R. O'Neil Officer | Jun 26, 2026 | 3,069 | $245.52K | Jun 26, 2026 | Restricted Stock |
| Eugene Schneider Officer | Jun 26, 2026 | 47,884 | $3.88M | Jun 26, 2026 | Stock Option Exercise |
| Eric Swayze Officer | Jun 25, 2026 | 10,602 | $839.29K | Jun 25, 2026 | Restricted Stock |
| Spencer R. Berthelsen Director | Jun 15, 2026 | 8,000 | $587.92K | Jun 15, 2026 | Stock Option Exercise |
| Holly B. Kordasiewicz Officer | Jun 12, 2026 | 60,846 | $4.47M | Jun 12, 2026 | Option Exercise |
| Spencer R. Berthelsen Director | Jun 1, 2026 | 8,000 | $605.36K | Jun 1, 2026 | Options Granted - 07/01/2016 |
| Brett P. Monia Officer | May 13, 2026 | 100,000 | $7.80M | May 13, 2026 | Stock Options |
| Joseph Loscalzo Director | May 4, 2026 | 54,321 | $4.35M | May 4, 2026 | Option Exercise |
| Joseph Baroldi Officer | Apr 28, 2026 | 1,626 | $116.73K | Apr 28, 2026 | Restricted Stock |
Congress trades
9 trades in Ionis Pharmaceuticals reported by 3 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Daniel Goldman NY10 | Sold | Mar 6, 2023 | $1K–15K | Apr 17, 2023 |
| Donna Shalala FL27 | Sold | Jun 24, 2019 | $1K–15K | Apr 27, 2020 308 days late |
| Donna Shalala FL27 | Bought | May 8, 2019 | $1K–15K | Apr 27, 2020 355 days late |
| Thomas MacArthur NJ03 · joint account | Bought | Nov 2, 2016 | $15K–50K | Dec 2, 2016 |
| Thomas MacArthur NJ03 · child | Bought | Nov 2, 2016 | $1K–15K | Dec 2, 2016 |
| Thomas MacArthur NJ03 · child | Bought | Nov 2, 2016 | $1K–15K | Dec 2, 2016 |
| Thomas MacArthur NJ03 · joint account | Bought | Feb 24, 2016 | $1K–15K | Mar 3, 2016 |
| Thomas MacArthur NJ03 · joint account | Bought | Feb 12, 2016 | $1K–15K | Mar 3, 2016 |
| Thomas MacArthur NJ03 · joint account | Sold | Feb 2, 2016 | $15K–50K | Mar 3, 2016 |
See a number that looks wrong?